期刊
AMERICAN HEART JOURNAL
卷 156, 期 6, 页码 1170-1176出版社
MOSBY-ELSEVIER
DOI: 10.1016/j.ahj.2008.07.004
关键词
-
资金
- American Heart Association (Dallas, TX)
- GlaxoSmithKline (Philadelphia, PA)
- National Institutes of Health (Bethesda, MD) [1K23HL085097]
- American Heart Association Pharmaceutical Roundtable [0675060N]
Background In chronic heart failure (HF), lower total cholesterol (TC) levels have been associated with increased mortality. However, the relationship between lipid levels and outcomes in acute HF has not been studied. This study investigates the relationship between cholesterol levels and in-hospital mortality in patients hospitalized with acute HF. Methods The Get With the Guidelines-Heart Failure registry prospectively collects data on patients hospitalized with HF. We analyzed data on 17,791 patients admitted between January 2005 and June 2007 at 236 participating hospitals who had TC levels recorded. Baseline patient characteristics, treatment regimens, and in-hospital mortality were examined by TC level (mg/dL) quartiles (Q) as follows: Q1 (TC <= 118), Q2 (TC 119-145), Q3 (TC 146-179), and Q4 (TC >= 180). Results Mean TC level was 150 47 mg/dL. Patients with lower TC were older and had higher prevalence of ischemic heart disease. Of the patients, 46% were on a lipid-lowering drug, including 58%, 50%, 43%, and 34% of patients in TC Q1 to Q4, respectively. In-hospital mortality in TC Ql to Q4 was 3.3%, 2.5%, 2.0%, and 1.3%, respectively (P < .0001). On multivariable adjusted analyses, each 10-mg/dL increase in TC level was associated with 4% decreased risk of in-hospital mortality (odds ratio 0.96, 95% CI 0.93-0.98). Conclusions In patients hospitalized with HF, lower TC levels independently predict increased in-hospital mortality risk. Further evaluation of optimal cholesterol levels and influence of lipid-lowering medication use on outcomes in this population is warranted. (Am Heart J 2008;156:1170-6.)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据